NEW YORK, December 29, 2025, 05:02 ET — Premarket
- BillionToOne shares last rose 3.4% to $89.30 at Friday’s close; they last traded at $89.40 in after-hours trading.
- The diagnostics maker’s most recent update showed 117% revenue growth in Q3 and operating income of $9.6 million.
- Investors are watching the company’s January presentation at the J.P. Morgan Healthcare Conference and its next earnings date in late February.
BillionToOne, Inc shares rose 3.4% to $89.30 at Friday’s close. The stock last traded at $89.40 in after-hours activity, trading that takes place after the regular session ends, according to Investing.com.
The newly public molecular diagnostics company heads into the final trading week of the year with few near-term catalysts before a big healthcare investor conference in January.
BillionToOne’s most recent quarterly report set a high bar: the company posted sharp revenue growth and swung to operating profit, while issuing full-year revenue guidance, it said in a results release filed with the U.S. securities regulator.
Total revenue climbed to $83.5 million in the third quarter ended Sept. 30, up 117% from a year earlier, the company said. Prenatal clinical testing revenue was $74.1 million, while oncology clinical testing revenue rose to $8.7 million from $1.1 million a year ago.
BillionToOne said it accessioned 162,900 tests — meaning samples received for processing — up 51% from a year earlier. It reported an overall average selling price, or ASP, of $501, a measure of average revenue per test delivered.
Gross margin, a measure of profitability after direct costs, rose to 70% from 53% a year earlier, the company said. Operating income was $9.6 million, compared with an operating loss of $12.6 million in the prior-year quarter.
“This quarter reinforced our view about how a unique, innovative technology combined with disciplined execution can drive a differentiated financial profile in molecular diagnostics,” Chief Executive Dr. Oguzhan Atay said. SEC
BillionToOne forecast full-year 2025 revenue of $293 million to $299 million and fourth-quarter revenue of $84 million to $90 million. It also said it expects positive GAAP operating income for both the fourth quarter and the full year.
The company said it raised gross proceeds of $314.0 million in its initial public offering, which closed on Nov. 7. BillionToOne priced its IPO at $60 a share, according to a Reuters report, putting the stock about 49% above that level at Friday’s close.
BillionToOne, based in Menlo Park, California, sells molecular diagnostics used in prenatal screening and oncology testing. Its core technology, Quantitative Counting Templates, is designed to count DNA molecules at the single-molecule level, the company said.
Investors will look for updates when management presents at the 44th Annual J.P. Morgan Healthcare Conference on Jan. 12, 2026, according to a company announcement.
Traders are also watching the company’s next earnings date, listed as Feb. 25, 2026, on Investing.com.
On the chart, the stock traded between $85.62 and $89.99 in the last regular session and has ranged from $81.51 to $138.70 over the past 52 weeks, according to Investing.com data.
